CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge
about
Diminished viral control during simian immunodeficiency virus infection is associated with aberrant PD-1hi CD4 T cell enrichment in the lymphoid follicles of the rectal mucosa.CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infectionStrategies to guide the antibody affinity maturation processCodelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques.Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.Oral Immunization with a Recombinant Lactococcus lactis-Expressing HIV-1 Antigen on Group A Streptococcus Pilus Induces Strong Mucosal Immunity in the Gut.Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus MacaquesSymmetry Controlled, Genetic Presentation of Bioactive Proteins on the P22 Virus-like Particle Using an External Decoration Protein.Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesJustification for the inclusion of Gag in HIV vaccine candidates.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.Development of targeted adjuvants for HIV-1 vaccinesA trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques.Hepatitis B Surface Antigen S Gene is an Effective Carrier Molecule for Developing GnRH DNA Immunocastration Vaccine in Mice.Intragastric administration of Lactobacillus plantarum and AT-2-inactivated SIV does not protect Indian rhesus macaques from intra-rectal SIV challenge nor reduce virus replication after transmission.
P2860
Q34364695-E7F992A0-4200-4E2F-9DFA-ABAD72B4F5BAQ35641018-D4DBB897-B177-49A5-9085-4FAB8264088FQ35685300-E1CFF1A2-CF85-4B80-8246-0F37A0ABACECQ35864543-8CA63E7B-8178-43F7-AA0F-818D8DCB09B5Q35914362-0118912F-4A98-418D-9DA0-4F09876F2854Q36008380-C53F0BBF-20E5-4A51-8202-2A212B40105DQ36260414-7C4540EB-9C3A-4DFB-A9B9-5DACBF056BCCQ36334371-A93B8B06-3C56-4600-9F42-1D5240689C0FQ36523998-EF56565B-575D-4570-9DDA-3156B55B5A74Q36892485-AD5BEC9E-AFAF-439F-B217-DFC8B4AB2CE0Q37253001-20A77035-1372-415E-9922-2289E4DF2325Q37522856-B3BB464E-3D9F-458E-BC09-726D24172131Q37621530-C772728B-4325-40FB-942B-1D8635EC16BBQ38662319-23A1DE75-C17B-432D-844B-94D1A42E1F2CQ38748193-67C0165D-AADB-4237-AC0F-692D0166724BQ40071705-4203BAF7-EC0E-400C-9863-9A6BAE48ED89Q40077472-623414DE-D377-45DD-BCCF-C507A49E168EQ40523370-686D9C09-DD23-4985-8E7E-940008040737Q41277922-E783286D-FC2F-4CDC-A94E-48A813ABB92CQ47296227-50B9A682-0E6B-499B-92BD-D5C861E1D2CDQ47873692-F8F63BB0-B2FA-4CA1-A427-AD5BEDAF046FQ52680808-36499EC8-8B98-4AEF-954E-DF953C63A2ED
P2860
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@ast
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@en
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@nl
type
label
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@ast
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@en
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@nl
prefLabel
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@ast
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@en
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@nl
P2093
P2860
P356
P1433
P1476
CD40L-adjuvanted DNA/modified ...... gous SIVE660 mucosal challenge
@en
P2093
Celia Labranche
Harriet L Robinson
Mariam Siddiqui
Pamela A Kozlowski
Rama Rao Amara
Sailaja Gangadhara
Suefen Kwa
Tianwei Yu
Vinod B Pillai
P2860
P304
P356
10.1128/JVI.00975-14
P407
P577
2014-06-11T00:00:00Z